TY - JOUR T1 - Evidence for the equilibrium between monomers and dimers of the death domain of the p75 neurotrophin receptor JF - bioRxiv DO - 10.1101/2021.05.02.442373 SP - 2021.05.02.442373 AU - Zhen Li AU - Zhi Lin AU - Carlos F. Ibáñez Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/05/03/2021.05.02.442373.abstract N2 - The p75 neurotrophin receptor (p75NTR) is an important mediator of synaptic depression and neuronal cell death, and its expression increases upon nerve injury and in neurodegenerative diseases. However, the molecular mechanisms leading to the activation of this receptor are still a matter of debate. The oligomerization properties of the death domain (DD) of p75NTR are critical for our understanding of the activation mechanisms of the receptor. In this paper, we present additional evidence supporting the existence of an equilibrium between monomeric and dimeric forms of the p75NTR DD in solution and in the absence of any other protein. Dynamic light scattering (DLS) measurements of native, untagged human p75NTR DD at room temperature yielded Rh=2.11 for this domain in 20mM phosphate buffer, corresponding to a molecular weight (MW) of approximately 19kDa, much closer to the theoretical MW of the homodimer (i.e. 21kDa) than the monomer. MWs deduced from the Rh of different control proteins used as standards were all congruent with their theoretical MWs. In addition, size-exclusion FPLC profiles of un-tagged human p75NTR DD in both HEPES and phosphate buffers revealed elution volumes corresponding to a MW of about 15kDa, which is intermediate between monomer and dimer, and indicative of dynamic monomer/dimer interconversion during the run. Together with our previous NMR studies, as well as biophysical data for other investigators, these results support the notion that the DD of p75NTR exists in equilibrium between monomers and dimers in solution, a notion that is in agreement with the oligomerization properties of all members of the DD superfamily.Competing Interest StatementThe authors have declared no competing interest. ER -